December 29, 2010 |
The outlook for venture-capital investment sounds similar to the prognostications for the rest of the economy in 2011: better than 2010. However, the recent survey by the National Venture Capital Association contains one worrisome sign for the Philadelphia region. Life sciences may no longer be ascendant. Attach your favorite reason for why that may be. The Food and Drug Administration is approving fewer new drugs than in the past. There is continuing uncertainty over how health-care reform will affect reimbursement for drugs and diagnostic tests.
January 19, 2014 |
Venture capitalists invested $420.3 million in Philadelphia-area companies last year, up 1.2 percent from the year before, according to the MoneyTree Report by PricewaterhouseCoopers L.L.P. and the National Venture Capital Association. The report, released Friday and based on data from Thomson Reuters, also showed that venture capitalists nationally invested $29.4 billion in 3,995 deals, a 7 percent increase in dollars and a 4 percent increase in deals. Locally, the number of companies receiving venture capital equity investments increased 9.9 percent to 122 from 111. In the fourth quarter, 34 Philadelphia-area companies received $81.6 million in investments.
August 8, 2007 |
A University City firm working on a way to diagnose Alzheimer's and Parkinson's diseases long before they present symptoms was the region's top magnet for venture capital during the second quarter. The firm, Avid Radiopharmaceuticals Inc., raised $26 million, according to the quarterly MoneyTree Survey released yesterday by PricewaterhouseCoopers and the National Venture Capital Association. "They have a deep understanding of the neurology segment and also the ability to apply their technology to other diseases, including diabetes," said Mike Pellini, vice president of the life-sciences group at Safeguard Scientifics Inc., of Wayne, which invested $7.3 million in Avid during the second quarter.
April 29, 2006 |
The flow of venture capital into Philadelphia-area companies slowed in the last quarter, but venture capitalists, ever mindful of how their industry crashed in 2001, say this year is off to a solid start. A quarterly survey of venture investing, released this week, shows 15 local companies were funded in the first quarter, the same number as in the final three months last year. But the amount of money invested in the Philadelphia area declined to $63.18 million in the first three months of 2006, compared with $117.
August 1, 2005 |
Investors usually love growth, but venture capitalists, craving stability after their industry crashed in 2001, say they're happy it has neither grown nor shrunk substantially since. A quarterly survey of venture investing, released last week, should keep them cheerful. The survey reported what it has for three years: The amount of money invested by venture capital funds in small, innovative companies has plateaued. Nearly $5.8 billion was invested in 750 companies in the second quarter of this year, according to the MoneyTree Survey by PricewaterhouseCoopers, Thomson Venture Economics, and the National Venture Capital Association.
January 28, 2005 |
Looking out of his office window in a Malvern corporate park, Paul L. Hallenbeck said it was the kind of neighborhood he had in mind last year as he pondered where to locate his new cancer-drug company, Neotropix Inc. Biotechnology company Gentara Corp. sits on one side and another, Cephalon Inc., soon will locate on the other, said Hallenbeck, a former top researcher at a Gaithersburg, Md., division of pharmaceutical firm Novartis AG. The Philadelphia region's multitude of life-sciences companies provides a supportive environment for a newcomer like Neotropix, Hallenbeck said.
October 25, 2005 |
Philadelphia area start-ups received $77.4 million in venture-capital financing in the third quarter, up 28.6 percent from the second quarter of the year, when $60.2 million was raised. But venture funding slipped 33 percent, compared with the third quarter of 2004, when 23 area firms attracted $116 million in funding, according to the MoneyTree Survey released today by PricewaterhouseCoopers, Thomson Venture Economics, and the National Venture Capital Association. For the first nine months of 2005, Philadelphia companies attracted $237.
April 30, 2004 |
Private investors in new technology companies, who were staggered by losses from the collapse of many Internet-based ventures just a few years ago, have regained their footing, largely by turning to health-care firms, an industry survey reports. These investors have been heartened by a surge in both initial public offerings and acquisitions. These two methods of selling companies in their portfolios had virtually dried up in recent years, discouraging investors from making commitments.
July 25, 2006 |
Venture-capital investing in the Philadelphia region reached its highest level since 2001 in the second quarter, driven by strong interest in biotechnology and life sciences. Two local companies, Tengion Inc. and Cardiokine Inc., were among the 10 biggest U.S. venture-capital investments across the country, receiving $50 million and $49.9 million, respectively, according to a quarterly survey released yesterday. Tengion, of King of Prussia, is developing replacement organs, starting with a bladder, using patients' own cells.
October 29, 2004 |
Vis.align Inc., of West Chester, could be a poster child for the state of the venture-capital industry. The information-technology company, built by private investors, is on the comeback trail from severe setbacks four years ago when the technology boom collapsed and it had to lay off hundreds of employees. It received $400,000 in the quarter ended Sept. 30, bringing to $9 million the amount it has raised over the last five years. Earlier this week, it was making a pitch at the Mid-Atlantic Venture Conference in Philadelphia for $5 million more, to buy smaller companies next year.